Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | $0.00 | $16.8M |
| Operating income | -$2.32M | -$6.86M | -$7.57M | -$32.4M |
| Operating margin | — | — | — | -193.1% |
| Net income | -$2.46M | -$7.38M | -$7.96M | -$43.3M |
| Net margin | — | — | — | -257.9% |
| EPS (diluted) | — | -$5.78 | -$14.27 | -$23.04 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$1.57M | -$981K | -$5.79M | -$22.6M |
| Capital expenditures | — | — | $0.00 | $99.0K |
| Free cash flow | — | — | -$5.79M | -$22.7M |
| Share buybacks | — | — | $75.0K | $0.00 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $100K | $100K | $513K | $18.0M |
| Total assets | $55.1K | $96.4K | $1.37M | $130M |
| Total liabilities | $3.76M | $6.54M | $4.08M | $91.5M |
| Shareholders' equity | -$3.71M | -$6.45M | -$2.71M | $38.9M |
| Retained earnings | -$6.14M | -$13.5M | -$21.5M | -$64.8M |
| Shares (wtd avg diluted) | 435K | 1.28M | 557K | 1.88M |
Every figure is extracted from Pelthos Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.